natgillin/translations-raw huggingface dataset:
Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival. 
Razen za na novo diagnosticirano KML v kronični fazi ni kontroliranih kliničnih preskušanj, ki bi dokazovala klinično koristnost, na primer izboljšanje bolezenskih simptomov ali povečano preživetje.
Manufacturer 
Izdelovalci:
Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment. 
400-miligramski odmerek imatiniba, je povzročilo zmanjšanje Cmax oziroma AUC(0-∞) za vsaj 54 % oziroma 74 % zadevnih vrednosti brez zdravljenja z rifampicinom.
The patients were distributed in three main categories: haematological failure (29%), cytogenetic failure (35%), or intolerance to interferon (36%). 
532 odraslih bolnikov so zdravili z začetnim odmerkom 400 mg. Bolniki so bili razdeljeni v tri glavne kategorije: hematološki neuspeh (29 %), citogenetični neuspeh (35 %) ali neprenašanje interferona (36 %).
- Do not breast-feed during the treatment with Imatinib Teva. 
Med zdravljenjem z zdravilom Imatinib Teva ne dojite.
Similar findings were found based on a 18months landmark analysis. 
Izsledki so bili podobni, če so odziv in število transkriptov ocenjevali pri 18 mesecih.
Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)*, pseudoporphyria* Musculoskeletal and connective tissue disorders Very common 
lihenoidna keratoza*, lichen planus*, toksična epidermalna nekroliza*, izpuščaj zaradi zdravila z eozinofilijo in sistemskimi simptomi (DRESSdrug rash with eosinophilia and systemic symptoms)* , psevdoporfirija*
Talk to your doctor before taking Imatinib Teva: - if you have or have ever had a liver, kidney or heart problem. 
Pred začetkom jemanja zdravila Imatinib Teva se posvetujte z zdravnikom: - če imate ali ste kdaj imeli težave z jetri, ledvicami ali srcem; - če jemljete zdravilo levotiroksin, ker so vam odstranili ščitnico.
Stop imatinib until ANC ≥ 
Prekinite zdravljenje z imatinibom dokler ni ANC ≥
Imatinib Teva is indicated for the treatment of 
Zdravilo Imatinib Teva je indicirano za zdravljenje:
Overall, in patients receiving first-line imatinib, the average daily dose delivered was 406 ±76 mg. 
Povprečni odmerek v skupini vseh bolnikov, ki so prejemali imatinib kot zdravilo prvega izbora, je bil 406 ± 76 mg na dan.
a 
V
In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; p=0.0001). 
Novo odkrita Ph+ ALL V kontrolirani študiji (ADE10) imatiniba v primerjavi z indukcijo s kemoterapijo pri 55 bolnikih z novo odkrito boleznijo, ki so bili stari 55 let ali več, je imatinib kot edino zdravilo povzročil značilno večji delež bolnikov s popolnim hematološkim odzivom kot kemoterapija (96,3 % v primerjavi s 50 %; p=0,0001).
Muscular weakness, arthritis, rhabdomyolysis/myopathy 
oslabelost mišic, artritis, rabdomioliza/miopatija pogostnost neznana:
This is because Imatinib Teva could cause hepatitis B to become active again, which can be fatal in some cases. 
- če ste kdaj bili ali ste sedaj okuženi z virusom hepatitisa B. Zdravilo Imatinib Teva namreč lahko povzroči ponovno aktivacijo hepatitisa B, kar utegne biti v nekaterih primerih smrtno nevarno.
Paediatric chronic phase CML (at dose 340 mg/m2) 
kronična faza KML pri pediatričnih bolnikih (ob odmerku 340 mg/m2)
There is limited experience in children with Ph-positive ALL and very limited experience in children with MDS/MPD, DFSP and HES/CEL. 
Izkušenj pri otrocih s KML, mlajših od 2 let, ni. Izkušnje so pri otrocih s Ph pozitivno ALL omejene, pri otrocih z MDS/MPD, DFSP in HES/CEL pa zelo omejene.
20x1 film-coated tablets 60 film-coated tablets 60x1 film-coated tablets 120 film-coated tablets 120x1 film-coated tablets 180x1 film-coated tablets 
20x1 filmsko obloženih tablet 60 filmsko obloženih tablet 60x1 filmsko obloženih tablet 120 filmsko obloženih tablet 120x1 filmsko obloženih tablet 180x1 filmsko obloženih tablet
Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose. 
Bolniki s poslabšanim delovanjem ledvic ali bolniki na dializi naj za začetni odmerek prejmejo najmanjši priporočeni odmerek 400 mg na dan.
MTX 12 mg intrathecal, day 1 
MTX 12 mg intratekalno, 1. dan
Chronic phase, newly diagnosed This phase III study in adult patients compared treatment with either single-agent imatinib or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C). 
V tej študiji tretje faze z odraslimi bolniki so primerjali zdravljenje z imatinibom kot edinim zdravilom na eni strani in s kombinacijo interferona alfa (IFN) s citarabinom (Ara-C) na drugi strani.
Hyper-CVAD regimen: CP 300 mg/m2 i.v. 
Indukcijsko-konsolidacijsko zdravljenje hiper-CVAD shema: CP 300 mg/m2 i.v.
A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial. 
V preskušanje stopnjevanja odmerka prve faze so vključili skupaj 26 pediatričnih bolnikov, starih < 18 let, bodisi s kronično fazo KML (n=11) bodisi s KML v blastni krizi ali Ph+ akutnimi levkemijami (n=15).
FIP1L1-PDGFRα fusion kinase was identified. 
Pri 61 od teh 117 bolnikov so odkrili FIP1L1-PDGFRα fuzijsko kinazo.
6400 mg (single dose): One case reported in the literature of one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, decreased neutrophil count, increased transaminases. 
Odmerek 6400 mg (enkraten odmerek): v literaturi je opisan en primer pri enem bolniku, pri katerem je prišlo do navzee, bruhanja, bolečin v trebuhu, zvišane telesne temperature, otekanja v obraz, zmanjšane koncentracije nevtrofilcev in zvišanja aminotransferaz.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state. 
Farmakokinetiko imatiniba so ovrednotili v območju odmerjanja od 25 mg do 1000 mg. Plazemski farmakokinetični profili so bili analizirani 1. dne, nato pa bodisi 7. bodisi 28. dne, ko so plazemske koncentracije že dosegle stanje dinamičnega ravnovesja.
The capsules are approximately 23 mm long and 9 mm wide. 
Kapsule so približno 23 mm dolge in 9 mm široke.
In non-clinical studies, the fertility of male and female rats was not affected (see section 5.3). 
Predklinične študje niso pokazale vpliva na plodnost pri podganjih samcih in samicah (glejte poglavje
Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases. 
Razen za novo diagnosticirano KML v kronični fazi ni kontroliranih preskušanj, ki bi pokazala klinično koristnost ali izboljšanje preživetja pri teh boleznih.
Additionally, partial cytogenetic response (PCyR) was observed in 16% for a MCyR of 81%. 
Poleg tega so zabeležili tudi delen citogenetični odziv (PCyR - partial cytogenetic response) pri 16 %
Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased 
zvišana vrednost kreatinina v krvi, zvišana vrednost kreatin-kinaze v krvi, zvišana vrednost laktat-dehidrogenaze v krvi, zvišana vrednost alkalne fosfataze v krvi redki:
Paediatric accelerated phase CML and blast crisis (starting dose 340 mg/m2) 
pospešena faza KML in blastna kriza pri pediatričnih bolnikih (začetni odmerek 340 mg/m2)
Blood amylase increased 
zvišana vrednost amilaze v krvi
Posology for MDS/MPD The recommended dose of Imatinib Teva is 400 mg/day for adult patients with MDS/MPD. 
Odmerjanje pri MDS/MPD Priporočeni odmerek zdravila Imatinib Teva pri odraslih bolnikih z MDS/MPD je 400 mg/dan.
Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion 
aritmija, atrijska fibrilacija, zastoj srca, miokardni infarkt, angina pektoris, perikardialni izliv pogostnost neznana:
Table 3 Response in adult CML study 
Preglednica 3 Odziv pri odraslih bolnikih s KML v kliničnih študijah
Prednisone 60 mg/m2 oral, days 1-7, 15-21; IDA 9 mg/m2 oral, days 1-28; 
prednizon 60 mg/m2 peroralno, 1.-7., 15.-21. dan; IDA 9 mg/m2 peroralno, 1.-28. dan;
Anaphylactic shock* Blood and lymphatic system disorders Very common 
Bolezni krvi in limfatičnega sistema zelo pogosti:
Headache2 
glavobol2
9/l and platelets ≥ 20 x 109/l, then resume treatment at 200 mg/m2. 
9/l in koncentracija trombocitov ≥ 20 x 109/l, nato spet začnite zdravljenje z odmerkom 200 mg/m2.
For doses of 400 mg and above (see dose recommendation below) a 400 mg film-coated tablet is available. 
Za odmerke 400 mg in več (glejte spodaj navedeno priporočeno odmerjanje) so na voljo 400 mg filmsko obložene tablete.
A total of 1.106 patients were randomised, 553 to each arm. Baseline characteristics were well balanced between the two arms. 
Randomiziranih je bilo skupno 1.106 bolnikov, 553 na vsak krak.
MTX 15 mg intrathecal, day 1; Methylprednisolone 40 mg intrathecal, day 1 
MTX 15 mg intratekalno, 1.dan; metilprednizolon 40 mg intratekalno, 1. dan
9/l and platelets ≥ 75 x 109/l. 
9/l in koncentracija trombocitov ≥ 75 x 109/l.
ANC < 1.0 x 109/l and/or platelets < 50 x 109/l 
ANC < 1,0 x 109/l in/ali koncentracija trombocitov < 50 x 109/l
h), days 2-3 (total of 8 courses) 
2.-3. dan (skupno 8 kur)
days 3-5; 
3.-5. dan;
The results observed in a population of 211 newly diagnosed Ph+ ALL patients in four uncontrolled clinical studies (AAU02, ADE04, AJP01 and AUS01) are consistent with the results described above. 
Pri populaciji 211 bolnikov z novo odkrito Ph+ ALL iz štirih nekontroliranih kliničnih študij (AAU02,
- The other ingredients are mannitol, crospovidone, magnesium stearate and silica colloidal anhydrous. 
- Druge sestavine zdravila manitol, krospovidon, magnezijev stearat, brezvodni koloidni silicijev dioksid.
- If you are unable to swallow the capsules, you can open them up and pour the powder into a glass of still water or apple juice. 
Če kapsul ne morete pogoltniti, jih lahko odprete in vsebino zmešate v kozarec navadne vode ali jabolčnega soka.
Hypertension, haematoma, subdural haematoma, peripheral coldness, hypotension, Raynaud's phenomenon 
hipertenzija, hematom, subduralni hematom, hladni distalni deli udov, hipotenzija, Raynaudov fenomen pogostnost neznana:
(1 h) days 4-5; Ara-C 2x 2 g/m2 i.v. 
(1 ura) 4.-5. dan; Ara-C 2x 2 g/m2 i.v.
This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to imatinib. 
Na ta opazovani dogodek, ki se veže na čas do dogodka, je močno vplival velik delež bolnikov, ki so z zdravljenja z IFN+Ara-C prešli na imatinib.
Periorbital oedema, dermatitis/eczema/rash 
periorbitalni edemi, dermatitis/ekcem/izpuščaj pogosti:
The tablets are approximately 20 mm long and 10 mm wide. 
Tablete so dolge približno 20 mm in široke 10 mm.
CHR: Study 0110 [WBC < 10 x 109/l, platelets < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5% and no extramedullary disease] NEL Same criteria as for CHR but ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l (0102 and 0109 only) RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver (only for 0102 and 0109). 
CHR študija 0110 [WBC < 10 x 109/l, trombociti < 450 x 109/l, mielociti+metamielociti < 5 % v krvi, brez blastov in promielocitov v krvi, bazofilci < 20 %, brez prizadetosti zunaj kostnega mozga] in v študijah 0102 in 0109 [ANC ≥ 1,5 x 109/l, trombociti ≥ 100 x 109/l, brez blastov v krvi, BM blasti < 5 % in brez bolezni zunaj kostnega mozga] NEL enaki kriteriji kot za CHR, a ANC ≥ 1 x 109/l in trombociti ≥ 20 x 109/l (samo 0102 in
Clinical studies in DFSP 
Odmerjanje pri DFSP
• Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems). 
• izpuščaj, rdeča koža z mehurčki na ustnicah, očeh, koži ali v ustih, luščenje kože, povišana telesna temperatura, rdeče ali vijolične lise nad nivojem kože, srbenje, pekoč občutek, gnojni izpuščaj
Calcium hydrogen phosphate Crospovidone 
Jedro tablete kalcijev hidrogenfosfat krospovidon magnezijev stearat
The printing ink is composed of shellac, iron oxide black (E172) and propylene glycol. 
Tiskarska barva pa vsebuje šelak, črni železov oksid (E172) in propilenglikol.
The age of these patients ranged from 3 months to 4 years and imatinib was given at dose 50 mg daily or doses ranging from 92.5 to 340 mg/m2 daily. 
Ti bolniki so bili stari od 3 mesece do 4 leta, imatinib pa so prejemali v odmerku 50 mg na dan ali v odmerkih od 92,5 do 340 mg/m2 na dan.
Palpitations, tachycardia, cardiac failure congestive3, pulmonary oedema 
palpitacije, tahikardija, kongestivno popuščanje srca3, pljučni edem redki:
Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated and treated. 
Srčni bolniki Srčne bolnike, bolnike z dejavniki tveganja za odpoved srca ali bolnike z anamnezo ledvične odpovedi je potrebno skrbno opazovati.
VCR 1.3 g/m2 i.v., day 1; Prednisolone 60 mg/m2 oral, days 1-5 
VCR 1,3 g/m2 i.v., 1. dan; prednizolon 60 mg/m2 peroralno, 1.-5. dan
In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/m2/day subcutaneously in combination with subcutaneous Ara-C 20 mg/m2/day for 10 days/month. 
Na kraku z imatinibom so bili bolniki zdravljeni s 400 mg na dan. Na kraku z IFN so bili bolniki zdravljeni 10 dni na mesec s tarčnim odmerkom IFN 5 MIU/m2/dan subkutano v kombinaciji s subkutanim Ara-C 20 mg/m2/dan.
Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides, CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5). 
Previdnost je potrebna pri uporabi imatiniba z zaviralci proteaze, azolnimi antimikotiki, določenimi makrolidi, s substrati CYP3A4 z ozkim terapevtskim oknom (na primer s ciklosporinom, pimozidom, takrolimusom, sirolimusom, ergotaminom, diergotaminom, fentanilom, alfentanilom, terfenadinom, bortezomibom, docetakselom, kinidinom) ali z varfarinom in drugimi derivati kumarina (glejte poglavje 4.5).
Some medicines can interfere with the effect of Imatinib Teva when taken together. 
Nekatera zdravila lahko ob sočasnem jemanju vplivajo na delovanje zdravila Imatinib Teva.
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib concentrations. 
Snovi, ki zavirajo aktivnost izoencima CYP3A4 citokroma P450 (na primer zaviralci proteaze, kot so indinavir, lopinavir/ritonavir, ritonavir, sakvinavir, telaprevir, nelfinavir, boceprevir; azolni antimikotiki vključno s ketokonazolom, itrokonazolom, posakonazolom, vorikonazolom; določenimi makrolidi kot so eritromicin, klaritromicin in telitromicin), bi lahko zmanjševale presnovo in zviševale koncentracije imatiniba.
When given with a high-fat meal, the rate of absorption of imatinib was minimally reduced (11% decrease in Cmax and prolongation of tmax by 1.5 h), with a small reduction in AUC (7.4%) compared to fasting conditions. 
11 %, tmax pa se je podaljšal za 1,5 ure), AUC pa se je v primerjavi z razmerami na tešče malo zmanjšala (7,4 %).
Dark yellow to brownish orange round film-coated tablets with a score line on one side. 
Temno rumena do rjavkastooranžna filmsko obložena tableta, okrogla in z zarezo na eni strani.
The adult patients reported in the published literature were treated with either 400 mg (4 cases) or 800 mg (1 case) imatinib daily. 
Odrasli bolniki, o katerih so pisali v objavljeni literaturi, so bili zdravljeni z odmerki bodisi 400 mg (v 4 primerih) ali pa 800 mg (v 1 primeru) imatiniba na dan. Do odziva je prišlo pri 5 bolnikih, pri 3 do popolnega in pri
Dose increases from 340 mg/m2 daily to 570 mg/m2 daily (not to exceed the total dose of 800 mg) may be considered in children in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response. 
Povečanje odmerka s 340 mg/m2 na dan na 570 mg/m2 na dan (ne sme preseči celotnega odmerka 800 mg) pride v poštev pri otrocih, ki nimajo hudih neželenih učinkov na zdravilo in hude nevtropenije ali trombocitopenije, ki bi bila povezana z levkemijo, in sicer v sledečih okoliščinah: napredovanje bolezni (kadarkoli); odsotnost zadovoljivega hematološkega odziva po najmanj 3 mesecih zdravljenja;
• Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red blood cells). 
• bledica, občutek utrujenosti in zasoplost in temen urin (znaki pomanjkanja rdečih krvničk),
Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onychoclasis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions 
urtikarija, ekhimoza, nagnjenost k podplutbam, hipotrihoza, hipopigmentacija kože, eksfoliativni dermatitis, lomljenje nohtov, folikulitis, petehije, psoriaza, purpura, hiperpigmentacija kože, bulozne erupcije redki:
• Reddening and/or swelling on the palms of the hands and soles of the feet which may be accompanied by tingling sensation and burning pain. 
• rdečina in/ali otekanje dlani in podplatov, lahko z občutkom mravljinčenja in s pekočo bolečino,
• Use about 50 ml for each 100 mg tablet. 
• Za vsako tableto po 100 mg potrebujete približno 50 ml vode.
MTX 15 mg intrathecal, day 1 
MTX 15 mg intratekalno, 1. dan
VCR (1.5 mg/m2/day, IV): days 1, 29 DEX (6 mg/m2/day, PO): days 1-5; 29-33 6-MP (75 mg/m2/day, PO): days 1-56 Methotrexate (20 mg/m2/week, PO): days 1, 8, 15, 22, 29, 36, 43, 50 G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG 
): 1. in 29. dan DEX (6 mg/m2/dan, peroralno): 1.-5. dan in 29.-33. dan 6-MP (75 mg/m2/dan, peroralno: 1.-5. dan metotreksat (20 mg/m2/teden, peroralno): 1., 8., 15., 22., 29., 36., 43. in 50. dan G-CSF = rastni dejavnik za granulocite (granulocyte colony stimulating factor), VP-16 = etopozid, MTX = metotreksat, i.v.
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop imatinib until 
tedne in še vedno ni povezana z levkemijo, prekinite zdravljenje z imatinibom,
Avascular necrosis/hip necrosis*, growth retardation in children* Renal and urinary disorders 
avaskularna nekroza/nekroza kolka*, zaostajanje v rasti pri otrocih*
• Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (e.g. high potassium, uric acid and calcium levels and low phosphorous levels in the blood). 
• občutek slabosti s siljenjem na bruhanje (navzea), zadihanost, neredno bitje srca, moten urin, utrujenost in/ali bolečine v sklepih skupaj z nenormalnimi izvidi laboratorijskih preiskav (na primer z visokimi vrednostmi kalija, sečne kisline in kalcija ter nizko vrednostjo fosforja v krvi),
Accelerated phase CML and blast crisis and Ph+ ALL (starting dose 600 mg) 
pospešena faza KML in blastna kriza in Ph+ ALL
Table 4 Chemotherapy regimen used in combination with imatinib 
Preglednica 4 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom Študija ADE10
The dose can be reduced if not tolerated (see section 4.2 and 5.2). 
Odmerek je mogoče zmanjšati, če ga bolnik ne prenaša dobro (glejte poglavji 4.2 in 5.2).
• Severe abdominal pain, blood in your vomit, stools or urine, black stools (signs of gastrointestinal disorders). 
• hude bolečine v trebuhu, kri v izbruhku, blatu ali urinu, črno blato (znaki bolezni prebavil),
Prednisolone 60 mg/m2/day oral 
prednizolon 60 mg/m2/dan peroralno
Renal failure chronic 
kronična ledvična bolezen
HES/CEL (starting dose 100 mg) 
HES/CEL (pri odmerku 400 mg)
Increased intracranial pressure, convulsions, optic neuritis 
zvišan intrakranialni tlak, konvulzije, optični nevritis pogostnost neznana:
Immune system disorders Not known 
Bolezni imunskega sistema pogostnost neznana:
1.5 x 109/l and platelets ≥ 75 x 109/l. 
1,5 x 109/l in koncentracija trombocitov ≥ 75 x 109/l.
Renal insufficiency 
Insuficienca jeter
In a study of fertility, in male rats dosed for 70 days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area. 
V študiji plodnosti na podganjih samcih, ki so dobivali zdravilo 70 dni pred parjenjem, se je pri odmerku 60 mg/kg, ki je približno enakovreden največjemu kliničnemu odmerku 800 mg/dan,
Chest pain, malaise 
bolečine v prsnem košu, slabo počutje
Flatulence, abdominal distension, gastro-oesophageal reflux, constipation, dry mouth, gastritis 
flatulenca, napihnjen trebuh, gastroezofagealni refluks, obstipacija, suha usta, gastritis občasni:
In newly diagnosed chronic phase CML grade 4 neutropenia (ANC < 0.5 x 109/l) and thrombocytopenia (platelet count < 10 x 109/l) were observed in 3.6% and < 1% of patients, respectively. 
V na novo diagnosticirani kronični fazi KML sta bili odkriti nevtropenija 4. stopnje (ANC < 0,5 x 109/l) in trombocitopenija 4. stopnje (< 10 x 109/l) pri 3,6
Gynaecomastia, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal oedema 
ginekomastija, erektilna disfunkcija, menoragija, neredne menstrualne krvavitve, motnje spolnih funkcij, boleče bradavice, povečanje dojk, edem skrotuma redki:
The increase is approximately 1.5 to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly. 
Gre za približno 1,5 do 2-kratno zvišanje, ki ustreza 1,5
30 hard capsules 30x1 hard capsules 90 hard capsules 90x1 hard capsules 
30 trdih kapsul 30x1 trdih kapsul 90 trdih kapsul 90x1 trdih kapsul
Haemolytic anaemia, thrombotic microangiopathy Metabolism and nutrition disorders Common 
hemolitična anemija, trombotična mikroangiopatija